Imbruvica keeps delivering with CLL combination data

12 December 2022

janssen_image_only_use_for_janssen_article_large

With Imbruvica (ibrutinib) sales of nearly $10 billion recorded by Janssen and AbbVie (NYSE: ABBV) combined in 2021, the blood cancer drug has already changed the standard of care for patients in certain settings.

The Bruton's tyrosine kinase (BTK) inhibitor is far from finished in showing its worth to patients, as displayed by data presented at the American Society of Hematology (ASH) Annual Meeting on Saturday.

"Ibrutinib has helped change the standard of care for adults living with CLL and other B-cell malignancies"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK